/ODTC
ODTC Stock - Odonate Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$22005.00+29.44%
+$5005.00 (+29.44%) • Jan 14
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.13
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $24205.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ODTC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21784.95 – $22225.05
TARGET (TP)$25305.75
STOP LOSS$20244.60
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.17
52W High$358000.00
52W Low$22005.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-21,000 | $-342,000 | $-1,051,000 | $-870,000 | $-381,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-817,000 | $-3,919,000 | $-46,822,000 | $-127,433,000 | $-114,930,000 |
| Net Income | $7.33M | $42.94M | $-68,315,000 | $-126,350,000 | $-111,825,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $6.82 | $39375.73 | $-48889.11 | $-102517.75 | $-107933.21 |
Company Overview
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ODTCBeat Rate
53%
Last 15 quarters
Avg Surprise
-4.2%
EPS vs Estimate
Beats / Misses
8/7
Last 12 quarters
Latest EPS
$-0.37
Q4 2021
EPS Surprise History
Q1 20
+9.1%
$-0.90vs$-0.99
Q2 20
+2.9%
$-0.99vs$-1.02
Q3 20
-11.2%
$-1.09vs$-0.98
Q4 20
+2.1%
$-0.93vs$-0.95
Q1 21
-6.4%
$-0.83vs$-0.78
Q2 21
-11.1%
$-0.90vs$-0.81
Q3 21
-75.8%
$-0.58vs$-0.33
Q4 21
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2022 | Nov 8, 2022 | — | — | — | — |
Q1 2022 | Feb 21, 2022 | — | — | — | — |
Q4 2021 | Nov 10, 2021 | — | $-0.37 | — | — |
Q3 2021 | Jul 27, 2021 | $-0.33 | $-0.58 | -75.8% | ✗ MISS |
Q2 2021 | May 14, 2021 | $-0.81 | $-0.90 | -11.1% | ✗ MISS |
Q1 2021 | Feb 23, 2021 | $-0.78 | $-0.83 | -6.4% | ✗ MISS |
Q4 2020 | Oct 28, 2020 | $-0.95 | $-0.93 | +2.1% | ✓ BEAT |
Q3 2020 | Jul 30, 2020 | $-0.98 | $-1.09 | -11.2% | ✗ MISS |
Q2 2020 | Apr 28, 2020 | $-1.02 | $-0.99 | +2.9% | ✓ BEAT |
Q1 2020 | Feb 20, 2020 | $-0.99 | $-0.90 | +9.1% | ✓ BEAT |
Q4 2019 | Nov 6, 2019 | $-1.06 | $-0.88 | +17.0% | ✓ BEAT |
Q3 2019 | Jul 24, 2019 | $-1.24 | $-1.15 | +7.3% | ✓ BEAT |
Q2 2019 | Apr 25, 2019 | $-1.24 | $-1.16 | +6.5% | ✓ BEAT |
Q1 2019 | Feb 22, 2019 | $-1.07 | $-1.17 | -9.3% | ✗ MISS |
Q4 2018 | Oct 23, 2018 | $-0.96 | $-0.98 | -2.1% | ✗ MISS |
Q3 2018 | Jul 30, 2018 | $-0.86 | $-0.79 | +8.1% | ✓ BEAT |
Q2 2018 | May 3, 2018 | $-0.87 | $-0.69 | +20.7% | ✓ BEAT |
Q1 2018 | Feb 14, 2018 | $-0.67 | $-0.81 | -20.9% | ✗ MISS |
Q4 2017 | Dec 8, 2017 | — | $-0.39 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.15 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ODTC
What is ODTC's current stock price?
Odonate Therapeutics, Inc. (ODTC) is currently trading at $22005.00 per share. The stock has moved +29.44% today.
What is the analyst price target for ODTC?
No analyst price targets are currently available for this stock.
What sector is Odonate Therapeutics, Inc. in?
Odonate Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ODTC's market cap?
Odonate Therapeutics, Inc. has a market capitalization of $8.05 billion, making it a mid-cap company.
Does ODTC pay dividends?
No, Odonate Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorESALY
Eisai Co., Ltd.
$61.51
Mkt Cap: $17.6B
GLSHQ
Gelesis Holdings, Inc.
$0.00
Mkt Cap: $0.0B
GNBT
Generex Biotechnology Corporation
$0.00
0HGENQ
Humanigen, Inc.
$0.00
Mkt Cap: $0.0B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
IMUN
Immune Therapeutics, Inc.
$0.09
Mkt Cap: $0.0B
IMVIQ
IMV Inc.
$0.00
Mkt Cap: $0.0B
JDHIY
JD Health International Inc.
$9.08
Mkt Cap: $29.1B
SRNEQ
Sorrento Therapeutics, Inc.
$0.03
Mkt Cap: $0.0B
TCON
TRACON Pharmaceuticals, Inc.
$0.03
Mkt Cap: $0.0B
Explore stocks similar to ODTC for comparison